Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 13,654 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.88, for a total value of $12,015.52. Following the sale, the insider now owns 26,346 shares in the company, valued at approximately $23,184.48. This trade represents a 34.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Galectin Therapeutics Price Performance

GALT stock opened at $1.15 on Friday. The stock has a market capitalization of $72.18 million, a PE ratio of -1.58 and a beta of 0.69. The company has a 50 day moving average price of $2.34 and a 200 day moving average price of $2.43. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $4.27.

Hedge Funds Weigh In On Galectin Therapeutics

Several large investors have recently made changes to their positions in GALT. JPMorgan Chase & Co. raised its holdings in Galectin Therapeutics by 161.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock worth $84,000 after purchasing an additional 18,907 shares during the last quarter. Barclays PLC raised its stake in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after buying an additional 21,598 shares during the last quarter. Soltis Investment Advisors LLC acquired a new position in Galectin Therapeutics in the third quarter valued at approximately $387,000. Geode Capital Management LLC boosted its stake in Galectin Therapeutics by 2.5% in the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after acquiring an additional 20,817 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new position in Galectin Therapeutics in the third quarter valued at approximately $117,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. HC Wainwright reissued a “neutral” rating on shares of Galectin Therapeutics in a report on Friday.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.